Weekly Lonapegsomatropin Outperforms Daily Growth Hormone in Young Chinese Children with GHD
Start here
Visen Pharma has reported a subgroup analysis of its China Phase 3 briGHt study in children with growth hormone deficiency. In patients aged 3 to 6 years, 52 weeks of treatment with once-weekly lonapegsomatropin produced an annualized height velocity 1.26 cm/year greater than a daily growth hormone formulation. The result adds to the evidence base for the weekly regimen in the youngest pediatric GHD population in China. Further details beyond this subgroup analysis, including outcomes in older age groups and any regulatory or labeling implications, are not part of the current report.
Written by a model from the reports · updated 4 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickChina Phase 3 briGHt Subgroup: Weekly Lonapegsomatropin Beat Daily GH by 1.26 cm/Year in Ages 3-6 GHD
Visen Pharma reported a subgroup analysis of the China Phase 3 briGHt study. In children with GHD aged 3-6 years, 52 weeks of once-weekly lonapegsomatropin produced an annualized height velocity 1.26 cm/year higher than a daily growth hormone formulation.
Heat trend for this story
Heat now 7·Peak in the comparable set 10 (Oct 23 18:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.